Mod GRF 1-29

Mod GRF 1-29 (Modified Growth Hormone Releasing Factor 1-29) is a stabilized synthetic analog of endogenous GHRH with four amino acid substitutions that resist enzymatic degradation. Unlike CJC-1295 with DAC, it lacks the Drug Affinity Complex and has a short 30-minute half-life, producing pulsatile GH release that closely mimics natural physiology. It is almost always co-administered with a GHRP such as ipamorelin.

Mod GRF 1-29 binds to and activates GHRH receptors on somatotroph cells of the anterior pituitary. The four amino acid substitutions (at positions 2, 8, 15, and 27) protect against dipeptidyl peptidase-IV cleavage and other serum proteases, extending bioactive duration beyond native GHRH (1-29) while maintaining pulsatility. Receptor activation triggers Gs-mediated adenylyl cyclase signaling, elevating intracellular cAMP, which drives GH synthesis and secretion. The resulting GH pulse stimulates hepatic IGF-1 production, skeletal muscle protein synthesis via IGF-1R/PI3K/Akt/mTOR pathways, lipolysis in adipose tissue via hormone-sensitive lipase activation, and collagen synthesis in connective tissue. Peak GH levels occur approximately 30 minutes post-injection, returning to baseline within 2–3 hours, preserving normal GH pulsatility over time.

Preclinical and early clinical research confirms Mod GRF 1-29 potently stimulates pulsatile GH release with a safety profile comparable to sermorelin. Human pharmacokinetic studies show peak GH levels 30–45 minutes post-injection with dose-dependent magnitude. The short half-life confers lower risk of receptor desensitization compared to long-acting GHRH analogs with DAC. Combination studies with ghrelin mimetics (ipamorelin, GHRP-6) demonstrate synergistic 3–10x amplification of GH pulse amplitude versus either agent alone. No large-scale human efficacy trials for body composition have been completed as of 2026.

Peptides commonly paired with Mod GRF 1-29 for synergistic effects.